MedTrace Logo

Feasibility of Ambulatory Talc. Pleurodesis

NCT06682936 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2024-11-12

No results posted yet for this study

Summary

Patients with malignant pleural disease often experience a significant symptom burden and a short life expectancy. The cornerstone of their treatment is relieving breathlessness by draining fluid from around the lungs and attempting to prevent further fluid build up. Inpatient chest drainage and talc pleurodesis remains the most successful method of stopping the fluid build up but this often requires an average hospital stay of four days. This can be an inappropriate length of time for this patient group. Our study would investigate whether this treatment could be provided on an outpatient, ambulatory basis and facilitate a greater quality of life.

The investigators would assess deliverability of the trial protocol and collect patient feedback to see if our patients consider it an acceptable and worthwhile intervention.

Conditions

  • Malignant Pleural Effusion
  • Malignancy
  • Palliative Care

Interventions

PROCEDURE

ambulatory chest drain and talc pleurodesis

a chest drain will be inserted, fluid drained and medical talc instilled on an ambulatory basis

Sponsors & Collaborators

  • David Rollins

    lead OTHER

Principal Investigators

  • Kevin Conroy, MBBS, FRCP · University Hospital of North Tees

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-10
Primary Completion
2025-01-31
Completion
2025-02-28

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06682936 on ClinicalTrials.gov